The objectives of this program are to train graduate students for a research career in academia, pharmaceutical companies, or government research agencies in the general area of pharmacology, with a focus on signal transduction, structural biology, neuropharmacology, and drug discovery. The program is designed to adapt to students' interest a will provide a strong biochemical, neuroscience, biophysical, and physiological background that will enable the student (1) to understand the molecular basis of currently used therapeutics; (2) to design experiments (a) to identify potential targets; and (b) t elucidate signal transduction mechanisms of new physiological agents or new therapeutics, (c) to solve macromolecular structures of interest in pharmacology, and (d) use modern tools for drug discovery. To achieve these ends, the pharmacology program at Yale was changed with new faculty and courses. Modern techniques in molecular pharmacology, cell and molecular biology, structural biology, chemistry, biochemistry, physiology and biophysics will be available to the trainee to achieve these goals. The trainee will have constant exposure to a variety of research programs of the faculty and over one hundred senior postdoctoral fellows who provide an additional resource for the trainees.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
4T32GM007324-40
Application #
9055706
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
1975-07-01
Project End
2017-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
40
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Yale University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Corbit, Kevin C; Camporez, João Paulo G; Edmunds, Lia R et al. (2018) Adipocyte JAK2 Regulates Hepatic Insulin Sensitivity Independently of Body Composition, Liver Lipid Content, and Hepatic Insulin Signaling. Diabetes 67:208-221
Greenlee, Etienne B; Stav, Shira; Atilho, Ruben M et al. (2018) Challenges of ligand identification for the second wave of orphan riboswitch candidates. RNA Biol 15:377-390
Miller, Chad J; Turk, Benjamin E (2018) Homing in: Mechanisms of Substrate Targeting by Protein Kinases. Trends Biochem Sci 43:380-394
Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Iwamoto, Daniel V; Huehn, Andrew; Simon, Bertrand et al. (2018) Structural basis of the filamin A actin-binding domain interaction with F-actin. Nat Struct Mol Biol 25:918-927
Lacy, Michael; Kontos, Christos; Brandhofer, Markus et al. (2018) Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4. Sci Rep 8:5171
Kadry, Yasmin A; Huet-Calderwood, Clotilde; Simon, Bertrand et al. (2018) Kindlin-2 interacts with a highly conserved surface of ILK to regulate focal adhesion localization and cell spreading. J Cell Sci 131:
Reshetnyak, Andrey V; Mohanty, Jyotidarsini; Tomé, Francisco et al. (2018) Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-?). Proc Natl Acad Sci U S A 115:8340-8345
Luciano, Amelia K; Zhou, Wenping; Santana, Jeans M et al. (2018) CLOCK phosphorylation by AKT regulates its nuclear accumulation and circadian gene expression in peripheral tissues. J Biol Chem 293:9126-9136

Showing the most recent 10 out of 91 publications